losartan has been researched along with fenofibrate in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Bairaktari, E; Elisaf, M; Siamopoulos, KC; Tsimichodimos, V | 1 |
| Elisaf, MS; Milionis, HJ | 1 |
| Bardin, T | 1 |
| Fukuchi, M; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Daskalopoulou, SS; Elisaf, M; Mikhailidis, DP; Tzovaras, V | 1 |
| Inokuchi, T; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Perez-Ruiz, F | 1 |
| Gerster, JC | 1 |
| Hisatome, I; Igawa, O; Ogino, K | 1 |
| Bundrick, JB; Litin, SC | 1 |
| Carmona, L; Herrero-Beites, AM; Perez-Ruiz, F | 1 |
| Kirch, W; Saar, J | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
5 review(s) available for losartan and fenofibrate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Losartan; Pyrroles; Uric Acid | 2005 |
[Involvement of the foot in metabolic diseases].
Topics: Achilles Tendon; Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Apatites; Chondrocalcinosis; Colchicine; Fenofibrate; Foot Diseases; Gout; Gout Suppressants; Hallux; Hemochromatosis; Humans; Hypercholesterolemia; Hyperostosis, Diffuse Idiopathic Skeletal; Hypolipidemic Agents; Losartan; Radiography; Renal Dialysis; Time Factors; Xanthomatosis | 2007 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Hypolipidemic Agents; Losartan; Uric Acid | 2008 |
2 trial(s) available for losartan and fenofibrate
| Article | Year |
|---|---|
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
Topics: Adult; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Fenofibrate; Gout Suppressants; Humans; Hypertension; Hypertriglyceridemia; Hyperuricemia; Hypolipidemic Agents; Losartan; Male; Middle Aged | 2003 |
Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases.
Topics: Adult; Antihypertensive Agents; Cholesterol; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hypolipidemic Agents; Hypoxanthine; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Time Factors; Triglycerides; Uric Acid; Xanthine | 2006 |
13 other study(ies) available for losartan and fenofibrate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Blood Chemical Analysis; Female; Fenofibrate; Humans; Hypertension; Hypolipidemic Agents; Losartan; Male; Middle Aged; Polypharmacy; Uric Acid | 1999 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Losartan; Male; Middle Aged; Risk Factors; Sodium Chloride Symporter Inhibitors; Uric Acid | 2000 |
Fenofibrate and losartan.
Topics: Drug Therapy, Combination; Fenofibrate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Losartan | 2003 |
New treatments for gout.
Topics: Allopurinol; Ascorbic Acid; Female; Fenofibrate; Gout; Gout Suppressants; Humans; Losartan; Male; Sensitivity and Specificity; Urate Oxidase; Uric Acid | 2007 |
Clinical pearls in general internal medicine.
Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Infective Agents, Urinary; Antihypertensive Agents; Calcium Channel Blockers; Creatinine; Diagnosis, Differential; Female; Fenofibrate; Gout; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Internal Medicine; Losartan; Male; Metformin; Nifedipine; Potassium; Sulfonamides; Tamsulosin; Trimethoprim; Ureteral Calculi; Vitamin B 12 Deficiency | 2011 |
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Topics: Aged; Cohort Studies; Colchicine; Crystallization; Female; Fenofibrate; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Prospective Studies; Regression Analysis; Secondary Prevention; Time Factors; Treatment Outcome; Uric Acid; Withholding Treatment | 2011 |
[A new application for well-known pharmaceutics--losartan and fenofibrate as potential remedies against gout?].
Topics: Angiotensin II Type 1 Receptor Blockers; Fenofibrate; Gout; Gout Suppressants; Humans; Hypolipidemic Agents; Losartan; Off-Label Use; Treatment Outcome; Uric Acid | 2014 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |